was revised in January 1990. The 'Loi Huriet' had little impact on the general public but it increased the awareness of the medical profession to clinical research and the requirements of GCP. It is widely believed that GCP will increase the credibility of the results from clinical research in France. Enforcement ofGCP in France is by an inspectorate backed by the law -'Loi Huriet'.
There are a number of unresolved issues such as the lack of GCP certification showing that the principles of GCP have been applied to a given clinical study. Also, there is no legal right of access to the source documents in France, not even for adverse event data, if no benefit accrues to the individual patient, and it will be necessary to find a way of examining source data for audit while maintaining confidentiality for the patient. The practical operation of the Committees for the Protection of Persons Participating in Medical Research, which have taken the place of ethics committees, has still to be determined. There is also the question of acceptability of European clinical trials to the FDA. In 1989, FDA inspectors audited 51 non-American clinical research centres including 20 in Canada and 10 in the Netherlands, but only two in England and one each in Scotland, France and Germany.
Inspectors for monitoring GCP in France, both doctors and pharmacists, have been trained and can enforce the law in a similar way to tax auditors; the penalties include fines of up to 200000 Francs and up to 2 years in prison for carrying out clinical trials without the consent of the patient, or approval of an ethics committee, or not complying with GCP standards; penalties can be applied equally to the sponsor and the investigator. Unlike the USA, there is no 'black list' of transgressors to disqualify unsuitable investigators. The aim of an inspection is verification of conformity to GCP and the validity of the data from the trial and it is done in two stages, the first covering the systems (sponsor, site, etc.) and the second the data. The first inspection of any institution is carried out on a voluntary basis possibly to make participants familiar with the procedure and purpose of the audit.
One important point, which Dr Steru stressed is that GCP can never make up for basic inadequacies in clinical trial design. The reactions of French clinical investigators to the introduction of GCP included complaints about adjusting to the new concept of informed consent, longer consultations with patients to deal with this and other aspects of trials, the loss of patients to other doctors who are not involved in clinical research and too much paper work and record keeping. GCP is also inimical to the aims of Phase IV clinical trials which are designed to determine the behaviour of a medicine in normal clinical practice.
Aspects of AIDS
However, the advantages of implementing GCP include generating a healthy and helpful climate between investigators, regulators and sponsors, improving the perception of clinical research and the reputation of clinical investigators, helping patients to comply with their treatments, and probably increasing the power of clinical trials.
Elsewhere in Europe, the Spanish have declared their intention of implementing GCP and monitoring its application by their Health Inspectorate, and certain general regulations applicable to clinical trials and GCP were issued in Germany earlier this year.
In conclusion, Dr Steru said that GCP is here to stay as it could be viewed as protection for the consumer and there could be no reversal of such safeguards. Furthermore, GCP is already established in the USA and Japan and Europe could not be seen to do any less. GCP could change the structure and development of clinical trials in Europe but it must not be allowed to substitute for good scientific method and practice.
This was a meeting that called to mind, perhaps unfairly, a 50-year-old aphorism: 'Too much emphasis on standards is a cause of decay; often it is a psychological defense mechanism set up by persons no longer productive.' (l Starr, J Clin Invest 1940; 19:765) . The warnings by the speakers against over-emphasizing the influence and worth of GCP will have to heeded if clinical research is to continue to benefit patients through the rapid identification and introduction of valuable new treatments. After all, GCP should be the servant of clinical research and not allowed to become some fearful monster.
Peter J Keen
Editorial Representative Library (Scientific Research) Section fungous infections (uncommon), cytomegalus inclusion virus (CMV) (uncommon), interstitial pneumonitis and pulmonary Kaposi's sarcoma (KS) were all considered.
There is a wide spectrum of severity, overlap of symptoms, atypical presentations and, in about 15% of AIDS patients with respiratory symptoms, more than one respiratory pathology is present. Most diagnoses can be made by bronchoscopy and bronchoalveolar lavage (BAL).
PCP, first described in 1940, occurred in immunodeficient patients but had a particular association with AIDS. Onset is insidious, from one week to 3 months, with worsening respiratory symptoms including fever and weight loss. Classical radiographic appearances are progressive fine perihilar The Royal Society of Medicine granular shadowing but over one third are atypical, eg with cavities and upper zone shadowing, and some show no changes. Effusions rarely occur. Non-invasive tests (eg transfer factor) in general lack specificity and diagnosis is by cytological demonstration of pneumocystis on BAL or induced sputum.
Mortality from pneumocystis had fallen from 30% in 1983-1987 to 9% in 1988-1989 although treatment had not changed. The possible reasons for this improved survival were considered. Secondary prophylaxis reduced the relapse rate of PCP and the value of primary prophylaxis had been established.
MTB is associated with AIDS, being a major factor in African AIDS. It might occur as a 'sentinel' disease preceding other manifestations or, if extrapulmonary or miliary would be a diagnostic criterion for AIDS. Extrapulmonary sites and unusual radiographic changes are seen more frequently in human immunodeficiency virus (HIV) seropositive patients. Smear negative and culture positive cases are more frequent. Histological diagnosis might be difficult because of poor granuloma formation. M avium intracellulare, carries a poor prognosis, less than 10% survival, with most anti-tuberculous drugs being of little proven value.
AIDS patients have a higher incidence of streptococcal and staphylococcal pneumonias, which tend to resolve slowly and might recur. Fungous infections are fortunately rare in this country but histoplasmosis and coccidioidomycosis are seen in endemic areas in USA.
Pulmonary KS occurs in 18-30% of patients with cutaneous KS. Survival rates without treatment are poor, with median survival of 1.5-3.8 months being reported. Diagnosis is by endobronchial visualization or biopsy and treatment by combination chemotherapy.
Survival from PCP and other respiratory infections has improved dramatically. It remained to be seen whether other 'new' respiratory manifestations of AIDS will develop as the use of antiretroviral agents and prophylaxis against common infections increases longevity in patients with HIV and very low T4 counts.
Professor Michael Harrison <MiddlesexHospital, London) described the neurological problems. Essentially, they are due to opportunistic infections or neoplasms of the central nervous system (CNS) or to direct effects of the virus. The cerebrospinal fluid (CSF), antibody and tissue responses are all modified by the acquired immune deficiency produced by the virus as was the therapeutic response.
Cryptococcus neoformans infection is not uncommon. Diagnosis is most reliably made by the cryptococcal polysaccharide antigen titre in the CSF but it is always necessary to examine with computerised tomography (CT) first to exclude cerebral mass lesions before lumbar puncture. Treatment needs to be life-long.
Toxoplasmosis is more common in areas with high environmental exposure, eg France and Florida. The characteristic CT signs are multiple lesions with ring enhancement, basal ganglia abscesses and focal oedema of the white matter. Magnetic resonance imaging (MRl) is also valuable, showing multiple lesions straddling grey-white matter boundaries. Treatment is very effective but needs to be life-long to prevent relapse. A papova virus can produce Journal of the Royal Society of Medicine Volume 83 October 1990 657 progressive multifocal leukoencephalopathy (PML) which produces progressive hemiparesis, field defects and aphasia and in which CT and MRI show white matter lesions which show little or no mass effect. There is as yet no treatment.
The common malignancy is lymphoma, either primary or secondary; KS is rare. Primary lymphoma can respond to radiotherapy but the prognosis for the patient is very poor as such lesions are usually a late complication.
Direct effects of HIV include abnormal CSF, low grade meningitis, spinal cord lesions occasionally producing paraplegia, and a painful sensory peripheral neuropathy. Cerebral effects are difficult to assess; the common postmortem finding is of a chronic encephalitis with multinucleate giant cells but the differential diagnosis between a dementia directly produced by the encephalitis and the effects of infections and other pathology is not easy, clinically.
Late effects shown on CT are cortical atrophy with wide sulci and large ventricles and abnormal areas on MRI related to encephalitis. Cognitive abnormalities have not been proven in otherwise asymptomatic subjects but surveys are under way to try to detect early signs so that the protective effect of anti-viral treatment (zydovine, DDI etc) could be monitored.
Dr Neil Smith (St John's Dermatology Centre, St Thomas' Hospital, London) described various cutaneous manifestations associated with HIV disease. These can be divided into infections, neoplastic disease and a miscellaneous group. Among cutaneous infections that are commonly seen in this group of patients are herpes simplex and zoster, molluscum contagiosum, viral warts and cytomegalo-virus (CMV). On some occasions CMV can be mistaken clinically for herpes simplex infections and both these infections commonly affected the perianal area.
Both superficial dermatophyte fungal infections and deep mycoses are encountered in patients with HIV disease and streptococcal infections are also seen. Scabies could be atypical with extensive crusted lesions resembling Norwegian scabies.
Kaposi's sarcoma is by far the commonest form of neoplasm seen in association with HIV infection but increasing numbers of high grade malignant lymphomas are also now being seen. The range of clinical presentations of Kaposi's sarcoma was illustrated and stress was laid on the early presentation in the oral cavity in many patients. As the lymphomas occurring within association with HIV infection are normally extranodal, these not uncommonly present in the skin or soft tissues.
Dr Brian Gazzard (Westminster Hospital, London) described the gastrointestinal aspects. Patients usually present with mouth symptoms, weight loss, diarrhoea and dysphagia. Weight loss can be secondary to opportunistic infection, diarrhoea, bizarre diet, or the effect of cytokines -eg tumour necrosis factor. Malabsorption is often present, either as a direct effect of HIV or secondary to infection; it has much in common with Kwashiorkor.
Dysphagia is usually painful. In a study threequarters of the cases were due to candidiasis. A quarter had oesophageal ulcers which were due to CMV in 25%. Endoscopy was much better at making the diagnosis (97.5% specificity) than barium swallow (25-45%). Although 96% of patients with oesophageal candidiasis had a good response to ketoconazole in 3 weeks there was an 80% relapse rate within 3 months.
Diarrhoea might be due to 'gay bowel' organisms, salmonella or opportunistic infections; Kaposi's sarcoma of the gut as a cause of diarrhoea is rare. Cryptosporodium (a common cause of traveller's diarrhoea) was found in up to 50% of cases. No pathology might be found. The most sensitive test was sigmoidoscopy and rectal biopsy (97%): colonoscopy came next (62%) and barium enema last (16%).
Sclerosing cholangitis was commonly found on endoscopic retrograde cholangiopancreatography (ERCP) in patients with right upper quadrant pain, probably due to cryptosporidiosis but CMV might be present.
CMV diarrhoea could be haemorrhagic with marked weight loss. Clinically, abdominal pain with marked rebound tenderness was a characteristic feature. On barium enema the appearances might resemble acute ulcerative colitis including toxic dilatation. In one third, the patient died because of colonic perforation.
The meeting ended with the Presidential Address by Dr Margaret Spittle, the President of the Section, on the 'Oncology of AIDS'. The major oncological problems are posed by Kaposi's sarcoma (KS) and non Hodgkins lymphoma (NHL). Hodgkin's disease, cloacogenic rectal carcinoma and head and neck carcinoma and teratoma can be seen and might be associated with the gay lifestyle or just occur in this age group of patients. The incidence of KS and NHL was 273 and 23 respectively in 1988 and 472 and 52 in 1989. Kaposi's sarcoma occurs in 40% of homosexuals with AIDS and 1% ofHIV positive haemophiliacs and blood transfusion recipients; the reported incidence seemed to be falling in New York.
On the nose and face, radiotherapy is very useful; a single dose is effective. Oedema of the legs and penis is common in peripheral disease in which 10 doses of 150 cGy is usually effective. In palatal lesions there Professor Hans H Peter (University of Freiburg, FRO) (with M Schlesier, J T Epplen) spoke on autoreactive T cells in rheumatic diseases with particular reference to Lyme arthritis. He said that the fact that most rheumatic diseases are associated with MHC gene products and that some show high titres of IgG autoantibodies argues in favour of a central role for T cells during initiation and perpetuation of inflammatory joint diseases. They performed a number oflimiting dilution (LD)culture experiments in order to elucidate the possible role of autoreactive T cells in rheumatic diseases. Autoreactivity in their studies refers to proliferative 'I'cells responses against either autologous antigen presenting cells alone or in the presence of potentially arthritogenic antigens such as type II collagen and U1-snRNP. In addition, could be an unusually aggressive reactive mucositis. Facial oedema also occurs and is resistant to treatment. Radiotherapy, chemotherapy and steroids have been used.
Role of infection in the aetiopathogenesis of inflammatory rheumatic diseases
The lungs are best treated by chemotherapy. The CT changes are more often positive than plain chest X-rays. A combination of bleomycin and vincristine can be used but might cause even more immunosuppression. A single nodular mass would respond to radiotherapy. Immunotherapy with interferons is liable to produce undesirable side-effects. It is necessary to differentiate between cosmetic and lifethreatening effects of the disease when planning treatment.
Non Hodgkin's lymphoma could be of High or Intermediate Grade and had a poor prognosis in HIV positive patients. It occurs in the central nervous system, the skin and other sites, and is often poorly differentiated with extranodal involvement. It could be very florid.
Brain lymphoma occurs in 25% of AIDS cases of lymphoma but in only 2% of non-AIDS cases. Diagnosis requires a neurological biopsy but this is often not possible. CT is not diagnostic. In a study, this disease was often terminal and 19 out of 36 were diagnosed at postmortem. In non-AIDS patients 11 out of 14 had a median survival of 5 months but in AIDS patients the prognosis was extremely poor; all were dead within 6 weeks. Treatment was ineffective but radiotherapy to the whole brain with intrathecal methotrexate had been used.
Outside the CNS, using less aggressive chemotherapy, the results were rather better, but it appears that 50% of AIDS patients will die from lymphoma. The UK AIDS Oncology group had been set up to study this problem.
PM Bretland

Editorial Representative
Section of Radiology they investigated T-cell responses against Borrelia burgdorferi (Bb) in some patients with Lyme arthritis (LA). First, they studied frequencies of autoreactive T cells (directed against autologous stimulator cells without exogenous antigen) in blood and synovial fluid of patients with rheumatoid arthritis eRA) and Lyme arthritis (LA). Roughly a lO-fold increase of autoreactive T cells was seen in blood and synovia of RA and LA patients (113000) as compared to blood of healthy volunteers (1120 000). This increase was not considered to be specific for rheumatic diseases since it was also seen in a patient with a viral infection. The majority of the established T-cell lines and clones appeared to be broadly reactive to autologous and allogeneic stimulator cells; only a minority of clones was strictly autoreactive. Most proliferative responses were inhibitable by anti-Dfl/Dl' monoclonal antibodies'.
From one patient (DRw11 homzygous, B27 +) a series of autoreactive T-cell clones were established among which one (UA-S2) proved to be specific from stimulator cells carrying the maternal but not the paternal DRwll haplotype'', Molecular analysis of
